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Objective: To determine the diagnostic accuracy of liver ultrasound for the detection of 
hepatoma in chronic liver disease (CLD) patients by either taking histopathology or serum 
α-fetoprotein levels or a biphasic computed tomography (CT) scan (whichever is available) as 
the gold standard.
Study design: Cross-sectional.
Place and duration of study: Radiology Department, The Aga Khan University Hospital, 
Karachi, Pakistan, from January 2007 to January 2010.
Methods: A total of 239 patients (156 males and 83 females) with clinical suspicion or 
  surveillance of hepatoma in CLD referred to the radiology department for ultrasound evaluation 
followed by either liver biopsy and histopathology or serum α-fetoprotein level or biphasic 
CT scan.
Results: The sensitivity of ultrasound for hepatoma detection in CLD was 65%, specificity 
was 85%, and accuracy was 70%, and positive predictive value and negative predictive value 
were 92% and 45%, respectively.
Conclusion: Ultrasound is a relatively quick, safe, reasonably accurate, and noninvasive imag-
ing modality for the detection of hepatoma in CLD and can be complemented with clinical 
assessment of screening high-risk patients.
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Introduction
Hepatocellular carcinoma (HCC) is the most common primary hepatic neoplasm that 
occurs in the setting of chronic liver disease (CLD) and cirrhosis.1 Ultrasound is the 
most commonly used imaging modality for screening CLD patients for the detec-
tion of tumor, because of its reliability, cost-effectiveness, and noninvasiveness.2 
The incidence of HCC in the US is rising and has nearly doubled in the past 15 years 
because of an increasing incidence of hepatitis B and C infections.3 In Pakistan, there 
is an incidence of 8/100,000 per annum4 and a prevalence of 3.7%,5 but it varies in 
the international data up to 39%.6–8 The accurate detection of HCC is critical for treat-
ment and management, especially in this modern era of improved surgical techniques, 
which include tumor resection, liver transplantation, transcatheter chemoemboliza-
tion, and radiofrequency ablation.9–11 Although serum α-fetoprotein levels are used to 
screen HCC in CLD patients, this test sometimes remains inconclusive;12–14 however, 
the cutoff value of α-fetoprotein above 400–500 ng/mL is considered diagnostic for 
hepatoma in CLD patients.15International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Imaging has a very important role to play. Ultrasound is 
the most widely used imaging modality for HCC screening 
in CLD patients. The sensitivity of ultrasound in the detec-
tion of HCC ranges from 59% to 84%16,17 with a specificity 
of 96%.18 Biphasic computed tomography (CT) scanning 
has a high sensitivity for detecting hepatoma, and earlier 
arterial enhancement and venous washout is diagnostic of 
hepatoma.14 Liver damaged by cirrhosis has benign lesions 
with areas of fat replacement, fibrotic scars, necrotic areas, 
or arteriovascular malformations that can mimic HCC 
and create diagnostic problems.19 Recent developments in 
ultrasound technology, such as Doppler ultrasound, power 
Doppler ultrasound, and contrast material-enhanced ultra-
sound, have shown promise for better characterization of 
liver lesions in patients with CLD.20,21 The data regarding 
ultrasound evaluation of hepatoma in CLD are limited from 
underdeveloped countries like Pakistan. Therefore, the 
objective of this study was to evaluate the role of grayscale 
and Doppler ultrasound in the detection of hepatoma in 
patients with CLD.
Material and methods
The participants of the study were included from patients 
referred to the radiology department of  The Aga Khan 
University Hospital, Karachi, Pakistan, for ultrasound evalu-
ation of the liver from January 2007 to January 2010, fol-
lowed by either liver biopsy or serum α-fetoprotein level or 
biphasic CT scan. Patients already known to have hepatoma 
were excluded. Ultrasound diagnosis of HCC was made if 
any two of the following findings were seen in the liver:
•	 Lesions smaller than 3 cm in diameter that appeared 
hypoechoic without posterior enhancement
•	 Any size lesion showing a heterogeneous mixed echoge-
nicity pattern
•	 Diffuse infiltrating lesion with irregular margins
•	 The presence of pseudocapsule in lesion
•	 Mass protruding beyond the surface of the liver
•	 Displacement or compression of intrahepatic blood 
vessels.
After at least 6 hours’ fasting, patients went through the 
ultrasound with a 3–6 Mhz curvilinear probe in a supine 
and oblique position, using departmental protocol. All 
examinations were performed and interpreted by creden-
tialed radiologists. Hard-copy images were also recorded 
for documentation. Data were entered and analyzed using 
SPSS (version 15, SPSS, Inc, Chicago, IL). Sensitivity, 
specificity, accuracy, and negative and positive predictive 
values of ultrasound for hepatoma were calculated using 
histopathologic findings.
Results
A total of 239 patients fulfilled the inclusion criteria of the 
study and were included. Ultrasonography of 239 consecu-
tive patients was carried out in the ultrasound suite of the 
hospital’s department of radiology. All the included patients 
were clinically suspected to have HCC by the referring 
  gastroenterologist. All these patients were already diag-
nosed to have CLD. A total of 156 (65%) patients among 
these were males and 83 (35%) were females. A wide range 
of age was seen (between 31 years and 70 years). Out of 
these 239 patients, ultrasound identified hepatoma in 126 
(53%) patients. Out of these, 117 (93%) were found to have 
  hepatoma on histopathology or serum α-fetoprotein level or 
a biphasic CT scan, whereas nine (7%) patients were false 
positive. Amongst the false-positive cases, seven patients 
were found to have metastatic disease and two patients had 
hemangiomas. A heterogeneous appearance of the lesion 
with greater than 5 cm size was the most common finding of 
hepatoma on ultrasound. This was seen in 62 of 117 cases. 
The presence of pseudocapsule was a frequent finding in true 
positive cases and was seen in 50% of the cases. Associated 
intrahepatic vascular displacement was found in 26% of 
the cases. A total of 113 (47%) were found to be negative 
on ultrasound. Out of these, 62 (55%) were found to have 
hepatoma. The rest of the patients (51 [45%]) were found to 
have changes of CLD.
Based on these findings, the sensitivity of ultrasound was 
found to be 65%, specificity 85%, positive predictive value 
92%, negative predictive value 45%, and accuracy 70% for 
diagnosing hepatoma in CLD patients.
Discussion
HCC is the most common primary liver cancer and usually 
occurs as a complication of CLD, most often arising in a cir-
rhotic liver. Therefore, accurate surveillance of patients with 
liver cirrhosis is of great clinical importance because they are 
at increased risk for hepatoma. Different clinical approaches 
are present for screening patients for hepatoma, including 
serum α-fetoprotein, ultrasonography, and CT. Ultrasound is 
a relatively safe, cost-effective, and easily available approach. 
In this study of 239 biopsied liver lesions we found sensitivity 
of ultrasound to be 65%, specificity 85%, positive predictive 
value 92%, negative predictive value 45%, and accuracy 70% 
for identifying hepatoma in CLD patients. These data are also International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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comparable with the international data. The international data 
show sensitivity of 59%16,17 and a specificity of 96%.17 In this 
study we have found 78 (66.6%) cases of HCC with HCV , 26 
(22.2%) cases with HBV positivity, three patients (2%) with 
both hepatitis B and C, seven (5.9%) patients with hepatitis 
B and D, and three (2%) patients with alcoholic cirrhosis. 
Similar results have been shown in studies from all over 
Pakistan. Farooqi and Farooqi22 found 67.86% cases to be 
positive for the hepatitis C virus and 14% with the hepatitis 
B virus. In a study from Lahore, around two-thirds of patients 
of HCC were seropositive for HCV , and the remaining cases 
were due to the hepatitis B virus alone or a coinfection with 
both viruses.23 The most common presentation of HCC on 
ultrasound in our study was of a heterogeneous lesion of 
mixed echogenicity pattern (53%) with size more than 5 cm, 
which is comparable with a study by Koteish and Thuluvath.17 
The other patterns found in our studies were lesions less than 
3 cm in size with a hypoechoic appearance on ultrasound 
(28%) and diffusely infiltrating hepatomas (19%). Associ-
ated findings with these lesions were intrahepatic venous 
thrombosis, which was seen in 26% cases of hepatoma, mass 
protruding beyond the surface of the liver in 9% cases, and 
displacement of intrahepatic blood vessels in 6% of the cases. 
The most common disease in our study that was confused 
for hepatoma in CLD patient was metastatic lesions in seven 
(6%) of 126 total positive cases on ultrasound. The other 
disease that was confused for hepatoma was hemangiomas 
in two (2%) of 126 total positive cases on ultrasound.
The reason for diagnostic difficulty was the   heterogeneity 
of these lesions on ultrasound. As the heterogeneous appear-
ance was the most common presentation of hepatoma on 
ultrasound, any heterogeneous lesion in CLD patients should 
be evaluated very cautiously. Because ultrasound is a quick, 
cost-effective, easily available tool, it can be used as an imme-
diate modality for evaluation of patients with CLD, especially 
in underdeveloped countries where affordability is a major 
issue and CT scans are not widely available. Our study has 
few limitations besides the single center and small sample size. 
A degree of experience among the radiologists in interpreta-
tions of ultrasound was not taken into account. Interobserver 
variability of ultrasound findings and patient-related factors 
were not assessed.
Conclusion
Ultrasound is a quick and cost-effective tool for the detection 
of hepatoma in clinically suspected cases and can be used as a 
screening tool in patients with CLD for surveillance of HCC.
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No funding or any other financial support was used for this 
study.
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